Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 9NIH 2NETWORK 2OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Endometrial Neoplasms 1

Interventions

Carboplatin 62Paclitaxel 61Specimen Handling 37Cisplatin 37Taxes 35Magnetic Resonance Spectroscopy 31Bevacizumab 30Immunoglobulin G 23Disulfides 23Biopsy 22Cyclophosphamide 19aldesleukin 17Topotecan 16Brachytherapy 16Radiotherapy 15Gemcitabine 15veliparib 14Oxaliplatin 13Doxorubicin 13temsirolimus 12fludarabine 12Platinum 12Docetaxel 121,2-diaminocyclohexaneplatinum II citrate 12olaparib 11liposomal doxorubicin 10cediranib 10Sirolimus 10Radiation 9Nivolumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Medroxyprogesterone Acetate × Gynecologic × Clear all
NCT03018249 2021-11-16

Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Completed
50 enrolled 12 charts
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

NCT00033358 2013-05-03

Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡